Inhibrx says INBRX-106 nearly doubles response rate in Phase 2
Inhibrx Biosciences reported that INBRX-106 nearly doubled response rate and achieved interim median PFS of 9.6 months in its Phase 2 HNSCC study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.